CA2800936A1 - Hapten conjugates for target detection - Google Patents
Hapten conjugates for target detection Download PDFInfo
- Publication number
- CA2800936A1 CA2800936A1 CA2800936A CA2800936A CA2800936A1 CA 2800936 A1 CA2800936 A1 CA 2800936A1 CA 2800936 A CA2800936 A CA 2800936A CA 2800936 A CA2800936 A CA 2800936A CA 2800936 A1 CA2800936 A1 CA 2800936A1
- Authority
- CA
- Canada
- Prior art keywords
- hapten
- conjugate
- antibody
- peroxidase
- subsequent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/52—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39894610P | 2010-07-02 | 2010-07-02 | |
| US61/398,946 | 2010-07-02 | ||
| US201161464216P | 2011-02-28 | 2011-02-28 | |
| US61/464,216 | 2011-02-28 | ||
| PCT/US2011/042849 WO2012003476A2 (en) | 2010-07-02 | 2011-07-01 | Hapten conjugates for target detection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2800936A1 true CA2800936A1 (en) | 2012-01-05 |
Family
ID=44583735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2800936A Abandoned CA2800936A1 (en) | 2010-07-02 | 2011-07-01 | Hapten conjugates for target detection |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20130109019A1 (enExample) |
| EP (1) | EP2588443A2 (enExample) |
| JP (1) | JP2013531801A (enExample) |
| AU (1) | AU2011274369A1 (enExample) |
| CA (1) | CA2800936A1 (enExample) |
| WO (1) | WO2012003476A2 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10267769B2 (en) | 2010-03-04 | 2019-04-23 | Ventana Medical Systems, Inc. | Processing system for processing specimens using acoustic energy |
| US10539487B2 (en) | 2010-03-04 | 2020-01-21 | Ventana Medical Systems, Inc. | Systems and methods for monitoring tissue sample processing |
| US10126216B2 (en) | 2011-02-17 | 2018-11-13 | Ventana Medical Systems, Inc. | Method for tissue sample fixation |
| WO2012003478A2 (en) | 2010-07-02 | 2012-01-05 | Ventana Medical Systems, Inc. | Detecting targets using mass tags and mass spectrometry |
| WO2013148498A1 (en) | 2012-03-27 | 2013-10-03 | Ventana Medical Systems, Inc. | Signaling conjugates and methods of use |
| WO2013167387A1 (en) | 2012-05-10 | 2013-11-14 | Ventana Medical Systems, Inc. | Uniquely specific probes for pten, pik3ca, met, top2a, and mdm2 |
| WO2014048942A1 (en) | 2012-09-25 | 2014-04-03 | Ventana Medical Systems, Inc. | Probes for pten, pik3ca, met, and top2a, and method for using the probes |
| JP6576835B2 (ja) * | 2013-03-12 | 2019-09-18 | ヴェンタナ メディカル システムズ， インク． | 標的物をｉｎｓｉｔｕ検出するための近接アッセイ |
| ES2804300T3 (es) | 2013-03-12 | 2021-02-05 | Ventana Med Syst Inc | Microscopía mejorada digitalmente para histología multiplexada |
| AU2014230469B2 (en) * | 2013-03-15 | 2017-07-13 | Ventana Medical Systems, Inc. | Spectral unmixing |
| WO2014151006A2 (en) | 2013-03-15 | 2014-09-25 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
| CN110669826B (zh) | 2013-04-30 | 2025-01-07 | 加州理工学院 | 通过顺序杂交编条形码的分子多重标记 |
| ES2729638T3 (es) * | 2013-10-11 | 2019-11-05 | Ventana Med Syst Inc | Ensayos múltiplex de tinción conjunta de receptores de HER2 y de estrógenos para detectar heterogeneidad tumoral |
| EP3617322A1 (en) | 2014-02-24 | 2020-03-04 | Ventana Medical Systems, Inc. | Automated rna detection using labeled 2 -o-methyl rna oligonucleotide probes and signal amplification systems |
| DK3149042T3 (da) | 2014-05-29 | 2019-11-04 | Spring Bioscience Corp | PD-L1-antistoffer og anvendelser deraf |
| BR112017000497B1 (pt) | 2014-07-11 | 2023-12-26 | Ventana Medical Systems, Inc | Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1 |
| WO2016124558A1 (en) | 2015-02-03 | 2016-08-11 | Ventana Medical Systems, Inc. | Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1) |
| EP3270160B1 (en) * | 2015-03-13 | 2020-03-18 | Sysmex Corporation | Method for detecting test substance and reagent kit used in said method |
| RU2743169C2 (ru) | 2015-11-06 | 2021-02-15 | Вентана Медикал Системз, Инк. | Репрезентативная диагностика |
| ES2886600T3 (es) | 2015-11-22 | 2021-12-20 | Ventana Med Syst Inc | Procedimientos de identificación de células inmunitarias en tejido tumoral positivo para PD-L1 |
| JP6876062B2 (ja) | 2016-01-26 | 2021-05-26 | ヴェンタナ メディカル システムズ， インク． | 自動ダイセクション、次世代シークエンシング、及び自動スライド染色装置を用いる、腫瘍のための予測診断ワークフロー |
| AU2017229370B2 (en) | 2016-03-08 | 2021-03-11 | Ventana Medical Systems, Inc. | Multiplexed immunohistochemistry using recombinant antibodies with epitope tags |
| JP6736921B2 (ja) * | 2016-03-10 | 2020-08-05 | コニカミノルタ株式会社 | Ｆｉｓｈ染色方法 |
| WO2017175523A1 (ja) * | 2016-04-06 | 2017-10-12 | コニカミノルタ株式会社 | 蛍光免疫染色法 |
| EP3475701B1 (en) | 2016-06-28 | 2023-02-22 | Ventana Medical Systems, Inc. | New colors for chromogenic ihc and ish staining with multi-dye quinone methide and tyramide conjugates |
| WO2018055014A1 (en) | 2016-09-23 | 2018-03-29 | Ventana Medical Systems, Inc. | Methods and systems for scoring extracellular matrix biomarkers in tumor samples |
| WO2018118786A1 (en) | 2016-12-19 | 2018-06-28 | Ventana Medical Systems, Inc. | Methods and systems for quantitative immunohistochemistry |
| EP3659110A1 (en) | 2017-07-24 | 2020-06-03 | Ventana Medical Systems, Inc. | Methods and systems for evaluation of immune cell infiltrate in tumor samples |
| EP3710820B1 (en) | 2017-11-13 | 2025-06-11 | F. Hoffmann-La Roche AG | Devices for sample analysis using epitachophoresis |
| ES2965647T3 (es) | 2018-01-31 | 2024-04-16 | Ventana Med Syst Inc | Procedimientos y sistemas para la evaluación de infiltrado de células inmunitarias en cáncer colorrectal en estadio III |
| WO2019224153A1 (en) | 2018-05-21 | 2019-11-28 | Genentech, Inc. | Her2 heterogeneity as a biomarker in cancer |
| CN108918896A (zh) * | 2018-05-29 | 2018-11-30 | 郑州左安检测科技有限公司 | 一种检测苯二氮卓的fitc试纸条及其制备方法和应用方法 |
| CN108957017A (zh) * | 2018-05-29 | 2018-12-07 | 郑州左安检测科技有限公司 | 一种检测苯二氮卓的试纸条及其制备方法和应用方法 |
| EP3824288A1 (en) | 2018-07-17 | 2021-05-26 | Ventana Medical Systems, Inc. | Materials and methods for detecting fusion proteins |
| CN112673258B (zh) | 2018-09-13 | 2025-07-25 | 文塔纳医疗系统公司 | 用于检测ntrk融合蛋白的组织化学和细胞化学方法 |
| JP7455816B2 (ja) * | 2018-09-20 | 2024-03-26 | ヴェンタナ メディカル システムズ， インク． | クマリン系架橋試薬 |
| CN112789684B (zh) | 2018-10-01 | 2025-05-09 | 文塔纳医疗系统公司 | 用于预测对pd-1轴导向疗法的应答的方法和系统 |
| WO2020074742A1 (en) | 2018-10-12 | 2020-04-16 | F. Hoffmann-La Roche Ag | Detection methods for epitachophoresis workflow automation |
| JP7548903B2 (ja) | 2018-11-20 | 2024-09-10 | ヴェンタナ メディカル システムズ， インク． | 形態学的特徴およびバイオマーカー発現のために細胞サンプルを調製および分析するための方法およびシステム |
| JP7411667B2 (ja) | 2019-02-05 | 2024-01-11 | ヴェンタナ メディカル システムズ， インク． | ステージｉｖの結腸直腸がんにおける免疫細胞浸潤の評価のための方法及びシステム |
| WO2020229437A1 (en) | 2019-05-14 | 2020-11-19 | F. Hoffmann-La Roche Ag | Devices and methods for sample analysis |
| WO2021041874A1 (en) | 2019-08-29 | 2021-03-04 | Martin David C | Biofunctional thiophene monomers |
| CN115552248A (zh) | 2020-05-07 | 2022-12-30 | 文塔纳医疗系统公司 | 用于评价肿瘤样品中egfr和egfr配体表达的组织化学系统和方法 |
| EP4204398A2 (en) * | 2020-08-28 | 2023-07-05 | Ventana Medical Systems, Inc. | Conjugates including a detectable moiety |
| WO2022063787A1 (en) | 2020-09-22 | 2022-03-31 | Roche Diagnostics Gmbh | Antibodies specific for alpha-1,6-core-fucosylated psa and fucosylated fragments thereof |
| CN113552362B (zh) * | 2021-07-23 | 2024-08-09 | 湖北百奥斯生物科技有限公司 | 一种新型信号放大的免疫荧光试剂盒 |
| WO2023058624A1 (ja) * | 2021-10-08 | 2023-04-13 | コニカミノルタ株式会社 | 染色方法、評価方法および標本 |
| CN116444424B (zh) * | 2023-06-16 | 2023-09-08 | 广东省大湾区华南理工大学聚集诱导发光高等研究院 | 一种基于聚集诱导发光的酪酰胺荧光材料、免疫组化染色试剂盒及其应用 |
| CN121844210A (zh) | 2023-07-07 | 2026-04-10 | 文塔纳医疗系统公司 | 用于评估细胞中er、pr和ki-67生物标志物的共定位的明场三重免疫组织化学测定 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2320387A1 (de) * | 1973-04-21 | 1974-10-31 | Boehringer Mannheim Gmbh | Phenoxyalkylcarbonsaeurederivate und verfahren zur herstellung derselben |
| US4469797A (en) | 1982-09-23 | 1984-09-04 | Miles Laboratories, Inc. | Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives |
| EP0292202B1 (en) * | 1987-05-19 | 1992-09-02 | FISONS plc | 2-(3,4-dihydroxyphenyl ethyl amines, their preparation and use as pharmaceutical compounds |
| DE3836656A1 (de) | 1988-10-27 | 1990-05-03 | Boehringer Mannheim Gmbh | Neue digoxigenin-derivate und ihre verwendung |
| US5455143A (en) * | 1991-10-25 | 1995-10-03 | Minnesota Mining And Manufacturing Company | Aminoketone sensitizers for aqueous soluble photopolymer compositions |
| PT1621554E (pt) | 1992-08-21 | 2009-07-13 | Univ Bruxelles | Imunoglobtainas desprovidas de cadeias leves |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| EP0933355A1 (en) * | 1997-12-24 | 1999-08-04 | Universiteit Maastricht | Preparation of tyramide conjugates |
| US6437146B1 (en) * | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
| US6372937B1 (en) | 1998-11-09 | 2002-04-16 | Mark Norman Bobrow | Enhanced catalyzed reporter deposition |
| US6387900B1 (en) * | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| ATE311378T1 (de) * | 1999-09-17 | 2005-12-15 | Nissan Chemical Ind Ltd | Benzopyran derivate |
| US6630469B2 (en) * | 2000-05-09 | 2003-10-07 | Bristol-Myers Squibb Company | 5-HT7 receptor antagonists |
| DE60112742T2 (de) * | 2000-05-19 | 2006-02-02 | Applied Research Systems Ars Holding N.V. | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit |
| US6649138B2 (en) | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
| US20020083888A1 (en) | 2000-12-28 | 2002-07-04 | Zehnder Donald A. | Flow synthesis of quantum dot nanocrystals |
| WO2003092043A2 (en) | 2001-07-20 | 2003-11-06 | Quantum Dot Corporation | Luminescent nanoparticles and methods for their preparation |
| WO2003057669A1 (fr) * | 2001-12-28 | 2003-07-17 | Takeda Chemical Industries, Ltd. | Antagonistes du recepteur androgene |
| EP1627420B1 (en) | 2003-05-07 | 2020-07-15 | Indiana University Research and Technology Corporation | Alloyed semiconductor quantum dots and concentration-gradient alloyed quantum dots, series comprising the same and methods related thereto |
| WO2005007621A2 (en) * | 2003-05-30 | 2005-01-27 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| JP4411153B2 (ja) * | 2003-07-18 | 2010-02-10 | 富士フイルム株式会社 | ２光子吸収色素消色材料、３次元的屈折率変調材料、３次元吸収率変調材料及び３次元光記録材料 |
| KR100657891B1 (ko) | 2003-07-19 | 2006-12-14 | 삼성전자주식회사 | 반도체 나노결정 및 그 제조방법 |
| DE10348022A1 (de) * | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| GB0324551D0 (en) * | 2003-10-21 | 2003-11-26 | Karobio Ab | Novel compounds |
| US7323567B2 (en) * | 2003-10-30 | 2008-01-29 | Boehringer Ingelheim (Canada) Ltd. | RSV polymerase inhibitors |
| TW200533357A (en) * | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| US20060246423A1 (en) | 2005-02-10 | 2006-11-02 | Adelson Martin E | Method and kit for the collection and maintenance of the detectability of a plurality of microbiological species in a single gynecological sample |
| CA2606018A1 (en) | 2005-04-28 | 2006-11-02 | Ventana Medical Systems, Inc. | Nanoparticle conjugates |
| ES2548518T3 (es) | 2005-11-23 | 2015-10-19 | Ventana Medical Systems, Inc. | Conjugado molecular |
| US7695929B2 (en) * | 2006-11-01 | 2010-04-13 | Ventana Medical Systems, Inc. | Haptens, hapten conjugates, compositions thereof and method for their preparation and use |
| JP2008228637A (ja) * | 2007-03-20 | 2008-10-02 | Tokushima Bunri Univ | 蛍光相関分光測定法を用いた過酸化水素量の測定方法及びその利用方法 |
| US20080299555A1 (en) * | 2007-05-30 | 2008-12-04 | Hiroaki Nitta | Multicolor chromogenic detection of biomarkers |
| WO2010121963A1 (en) * | 2009-04-21 | 2010-10-28 | Nerviano Medical Sciences S.R.L. | Resorcinol derivatives as hsp90 inhibitors |
| WO2012003478A2 (en) * | 2010-07-02 | 2012-01-05 | Ventana Medical Systems, Inc. | Detecting targets using mass tags and mass spectrometry |
-
2011
- 2011-07-01 JP JP2013518768A patent/JP2013531801A/ja active Pending
- 2011-07-01 US US13/805,978 patent/US20130109019A1/en not_active Abandoned
- 2011-07-01 EP EP11738526.0A patent/EP2588443A2/en not_active Withdrawn
- 2011-07-01 CA CA2800936A patent/CA2800936A1/en not_active Abandoned
- 2011-07-01 WO PCT/US2011/042849 patent/WO2012003476A2/en not_active Ceased
- 2011-07-01 AU AU2011274369A patent/AU2011274369A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011274369A1 (en) | 2012-12-06 |
| WO2012003476A3 (en) | 2012-05-03 |
| WO2012003476A2 (en) | 2012-01-05 |
| EP2588443A2 (en) | 2013-05-08 |
| JP2013531801A (ja) | 2013-08-08 |
| US20130109019A1 (en) | 2013-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20130109019A1 (en) | Hapten conjugates for target detection | |
| JP7000489B2 (ja) | ハプテン、ハプテンコンジュゲート、その組成物ならびにそれらの製造および使用の方法 | |
| US11906523B2 (en) | Signaling conjugates and methods of use | |
| JP6473381B2 (ja) | 免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体 | |
| US9696310B2 (en) | Molecular sensor and methods of use thereof | |
| KR102846425B1 (ko) | 시아닌계 화합물, 이를 포함하는 생체분자 표지용 염료, 키트 및 조영제 조성물 | |
| US11597842B2 (en) | Labeling dye and kit including same | |
| JP2022526907A (ja) | 光親和性プローブ | |
| CN111491667A (zh) | 肽核酸缀合物 | |
| CN114315783A (zh) | 生色过氧化物酶底物 | |
| AU2020264322B2 (en) | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | |
| JP2859893B2 (ja) | フェナリンイミン蛍光色素並びに該色素の分析組成物、分析要素及び分析方法への利用 | |
| AU2019208215B2 (en) | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | |
| KR20230019546A (ko) | 신규 화합물 또는 이의 염, 이를 포함하는 시스테인 탐지용 조성물, 형광 프로브 및 암 진단용 조성물, 시스테인 검출방법, 암 진단을 위한 정보를 제공하는 방법 및 신규 화합물의 제조방법 | |
| Krieg et al. | Novel oxidative self-anchoring fluorescent substrates for the histochemical localization of endogenous and immunobound peroxidase activity | |
| JP7849883B2 (ja) | 生体分子構造検出用プローブ、生体分子構造検出用キット、及び生体分子構造の検出方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20160704 |